Drug intelligence / Profile preview

Yanhouning

Development stage: Unknown
Lead developer: Suzhou Yusen New Drug Development
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Yanhouning is a botanical oral liquid developed by Suzhou Yusen New Drug Development Co., Ltd. for the treatment of acute pharyngitis. It is formulated based on Traditional Chinese Medicine (TCM) principles to treat the 'wind-heat invading outward' syndrome, a classification used to describe symptoms such as sore throat, fever, and pharyngeal inflammation. The drug is currently undergoing Phase II clinical evaluation in China (CTR20250933) to determine its optimal dosage, efficacy, and safety profile in patients presenting with acute pharyngeal symptoms.

Brand names: Yanhouning
Other names: Yanhouning Oral Liquid

Beyond the preview

Go deeper on Yanhouning.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yanhouning.

Explore the full profile